Labiana Health

Labiana Health Total Assets

The Total Assets of Labiana Health (LAB.MC) as of Oct 26, 2026 is 57.54 M EUR. In the previous year, Total Assets was 52.00 M EUR — a change of 10.66% (higher).

Total Assets

57.54 MEUR

YoY

10.66%

Last updated:

Total Assets of Labiana Health is 2025 57.54 M EUR. Total Assets of Labiana Health was 2024 52.00 M EUR. It decreases by 10.66% higher compared to the previous year.

The Labiana Health Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
41.99 M EUR
Jan 1, 2019
60.43 M EUR
Jan 1, 2021
68.37 M EUR
Jan 1, 2022
60.78 M EUR
Jan 1, 2023
59.12 M EUR
Jan 1, 2024
52.00 M EUR
Jan 1, 2025
57.54 M EUR
The Labiana Health Total Assets history
YEARTotal AssetsYoY
57.54 MEUR+10.66%
52.00 MEUR-12.05%
59.12 MEUR-2.72%
60.78 MEUR-11.10%
68.37 MEUR+13.14%
60.43 MEUR+43.92%
41.99 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Total Assets of Labiana Health is 57.54 M EUR in 2025.

Total Assets of Labiana Health changed from 52.00 M EUR to 57.54 M EUR, representing a 10.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labiana Health

All Key Metrics — Labiana Health